.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

OncClub: Join the Chat on Trending Trials in Cancer
Final results from the Phase 3 ClarIDHy trial
Lively expert panel discussions featuring peer-to-peer exchanges
Long-term efficacy and safety of TRK fusion-positive lung cancer treatment

SpecialtySee All >

Biosimilars
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Oncology
Head & Neck Cancers
Hematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Multiple Myeloma

Advertise
About OncLive
Editorial Board
CureToday.com
TargetedOnc.com
CancerNetwork.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Future Strategies in Kidney Cancer Treatment

EP. 1: Understanding the Biology of Kidney Cancer

July 17th 2017

EP. 2: Kidney Cancer: Continuing to Improve Survival

July 17th 2017

EP. 3: Frontline TKI Strategies in Kidney Cancer

July 17th 2017

EP. 4: Role of mTOR Inhibition in Kidney Cancer

July 17th 2017

EP. 5: mTOR/TKI Combination Therapy in Kidney Cancer

July 17th 2017

EP. 6: Practical Experience With Lenvatinib/Everolimus in RCC

July 17th 2017

EP. 7: Immunotherapy in Kidney Cancer

July 17th 2017

EP. 8: New Strategies in Kidney Cancer

July 17th 2017

EP. 9: Anti-VEGF/Immunotherapy Combinations in Kidney Cancer

July 17th 2017

EP. 10: Novel Combinations in Kidney Cancer

July 17th 2017